Clinical and non-clinical aspects of reimbursement policy for orphan drugs in selected European countries.

MLA

Jakubowski, Szczepan, et al. “Clinical and Non-Clinical Aspects of Reimbursement Policy for Orphan Drugs in Selected European Countries.” Frontiers in Pharmacology, Dec. 2024, pp. 1–17. EBSCOhost, https://doi.org/10.3389/fphar.2024.1498386.

APA

Jakubowski, S., Holko, P., Nowak, R., Warmuth, M., Dooms, M., Salminen, O., Cortial, L., Selke, G. W., Georgi, C., Magnússon, E., Crisafulli, S., Strijbosch, F., Mueller, T., Grieve, E., Danés, I., & Kawalec, P. (2024). Clinical and non-clinical aspects of reimbursement policy for orphan drugs in selected European countries. Frontiers in Pharmacology, 1–17. https://doi.org/10.3389/fphar.2024.1498386

Chicago

Jakubowski, Szczepan, Przemysław Holko, Rafał Nowak, Marisa Warmuth, Marc Dooms, Outi Salminen, Lucas Cortial, et al. 2024. “Clinical and Non-Clinical Aspects of Reimbursement Policy for Orphan Drugs in Selected European Countries.” Frontiers in Pharmacology, December, 1–17. doi:10.3389/fphar.2024.1498386.